Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting

Phase 3

GivinostatEfficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Sponsor:

Italfarmaco

Code:

NCT05933057

Conditions

Duchenne Muscular Dystrophy

Eligibility Criteria

Sex: Male

Age: 9 - 17

Healthy Volunteers: Not accepted

Interventions

Givinostat

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by Italfarmaco on 2025-03-27.